NASDAQ · Biotechnology

MAZE (MAZE) Stock

$26.72 +0.72% NASDAQ: MAZE Healthcare

Valuation

MetricValue
Price$26.72
Market Cap$1.48B
P/E Ratio-8.11
P/B Ratio3.86
P/S Ratio67.80
EPS (TTM)$-3.05
52-Week High$53.65
52-Week Low$9.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-36.90%
ROA-33.00%
ROCE-40.28%
Gross Margin92.04%
Operating Margin-6.70%
Net Margin-6.13%
Debt/Equity0.18
Current Ratio15.22

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$168.0M$0
Operating Profit$-111.0M$-99.0M$58.0M$-143.0M
Net Profit$-115.0M$-100.0M$52.0M$-131.0M
EPS$-2.63$-2.29$0.08$-3.05
Op Margin——34.4%—

Balance Sheet (USD)

Metric2022202320242025
Total Assets$150.0M$72.0M$241.0M$397.0M
Total Liabilities$49.0M$61.0M$44.0M$42.0M
Cash$100.0M$29.0M$197.0M$189.0M
Borrowings$32.0M$50.0M$27.0M$23.0M

Latest News

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? Motley Fool · Jun 29, 2026 Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk Simply Wall St. · Jun 13, 2026 Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now Insider Monkey · Jun 8, 2026 Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? Motley Fool · Jun 5, 2026 Maze Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-99.0M$-87.0M$76.0M$-112.0M
Investing Cash Flow$-5.0M$-1.0M$-2.0M$-172.0M
Financing Cash Flow$0$0$0$0
Net Cash Flow$-101.0M$-71.0M$168.0M$-8.0M
Free Cash Flow$-101.0M$-87.0M$75.0M$-113.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.19
EV / EBITDA-10.26
FCF Yield-7.22%
Quick Ratio18.31
Interest Coverage-81.03
Return 1Y56.97%
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.46%
Institutions Held95.12%
Institutions Float Held96.54%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 4,567,2742026-03-31
TRV GP IV, LLC4,473,9582026-03-31
Arch Venture Management, Llc4,120,0532026-03-31
Deep Track Capital, Lp3,477,5622026-03-31
Janus Henderson Group PLC2,858,8762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARDX $3.80 +1.06% 11.04 $938.71M 0.00%
BCRX $10.17 +2.52% -7.07 $2.58B 0.00%
IMNM $27.33 +0.98% -8.13 $2.61B 0.00%
NTLA $12.76 +0.59% -3.80 $1.78B 0.00%
PHVS $35.17 +0.69% -9.75 $2.46B 0.00%

About MAZE

MAZE is led by CEO Jason V. Coloma, publicly traded since 2025.

MAZE stock trades at $26.72 with a market capitalization of $1.48B. The stock is valued at a price-to-earnings (P/E) ratio of -8.11, price-to-book of 3.86, price-to-sales of 67.80. Over the past 52 weeks the stock has ranged between $9.83 and $53.65, and currently trades 50.2% below its 52-week high.

On profitability, MAZE generates a return on equity (ROE) of -36.90%, return on capital employed of -40.28%, an operating margin of -6.70%, a net profit margin of -6.13%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides